APP and Alzheimer disease: Thus, the attempt to employ the targeted iAβ degradation therapy alone in symptomatic AD faces a classic Catch-22 conundrum: To reduce iAβ levels sufficiently to stop the operation of the AβPP-independent iAβ generation pathway, this pathway should first be inactivated.